Artivion, Inc.
NYSE:AORTMedical - Devices
-$0.11 today
- Market cap
- $904.56M
- Beta
- 1.26
- P/E (TTM)
- 86.7
- EPS (TTM)
- $0.24
Volume 0.91M
Average 0.64M
AORT Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Artivion, Inc.NYSE: AORT
Gross Profit · Q1 FY2026 · quarter ended Mar 2026
Gross profit grows, but more slowly than its trailing trend
Q1 FY2026 gross profit of $71.54M rose 12.5% year over year, behind the +15.8% change in trailing-twelve-month gross profit. Sequentially, it rose 2.7% from the prior quarter. Over 3 fiscal years it compounded at +10.1% a year.
Context
- Gross profit amounted to 61.3% of revenue in FY2025, down 2.7 pp from a year earlier.
- Gross profit increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +12.5% toward the trailing-twelve-month pace of +15.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 270.45M USD
- Year-over-year change
- +8.7%
- 4-year CAGR
- +8.2%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 270.45M | +8.7% |
| FY2024 | 2024-12-31 | 248.78M | +8.6% |
| FY2023 | 2023-12-31 | 229.18M | +13.2% |
| FY2022 | 2022-12-31 | 202.52M | +2.5% |
| FY2021 | 2021-12-31 | 197.51M | — |
Gross Profit vs competitors
How AORT compares with its peers on the latest reported figures
- AORT's LTM Mar 2026 gross profit of $288.7M is the 8th highest of the 11 companies compared; the peer median is $431.73M.
- Its year-over-year change of +15.8% is the 5th highest of 11, against a peer median of +10.7%.
- Gross profit amounts to 62.9% of revenue for AORT, versus a peer median of 48.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ARDTArdent Health Partners, LLC | LTM Mar 2026 | $3.2B | -30.5% | +13.9% | 49.7% |
| LTM Jun 2026 | $774.11M | +6.4% | +31.6% | 86.1% | |
| LTM Jun 2026 | $531.85M | +24.2% | +24.8% | 33.6% | |
| LTM Jun 2026 | $477.75M | +15.1% | +15.5% | 32.4% | |
| LTM Jul 2026 | $436.92M | -2.4% | +7.1% | 23.7% | |
| LTM Sep 2026 | $426.54M | -49.7% | +7.9% | 14.5% | |
| LTM Jun 2026 | $416.98M | +2967.4% | +123.0% | 92.5% | |
| LTM Mar 2026 | $288.7M | +15.8% | +10.1% | 62.9% | |
| LTM Mar 2026 | $202.81M | +29.8% | +74.3% | 63.0% | |
| LTM Mar 2026 | $23.44M | +226.7% | +241.8% | 48.4% | |
| LTM Jun 2026 | -$2.33M | -101.6% | — | — | |
| Peer median (excluding AORT) | $431.73M | +10.7% | +24.8% | 48.4% | |
Competitors are the stored peer set for AORT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 298.84M | 313.79M | 354M | 388.54M | 441.33M |
| Cost of Revenue | 101.32M | 111.27M | 124.83M | 139.76M | 170.88M |
| Gross Profit | 197.51M | 202.52M | 229.18M | 248.78M | 270.45M |
| Gross Margin | 66.1% | 64.5% | 64.7% | 64.0% | 61.3% |
| Research & Development | 35.55M | 38.88M | 28.71M | 28.45M | 30.99M |
| Selling, General & Admin | 169.77M | 157.44M | 208.98M | 192.38M | 212.72M |
| Operating Expenses | 189.4M | 196.32M | 223.43M | 209.91M | 243.71M |
| Depreciation & Amortization | 23.98M | 22.44M | 23.08M | 24.21M | 22.46M |
| EBITDA | 26.04M | 25.68M | 26.79M | 50.97M | 63.82M |
| EBITDA Margin | 8.7% | 8.2% | 7.6% | 13.1% | 14.5% |
| Operating Income | 8.12M | 6.2M | 5.74M | 38.87M | 26.75M |
| Operating Margin | 2.7% | 2.0% | 1.6% | 10.0% | 6.1% |
| Interest Income | 79K | 147K | 1.08M | 1.47M | 763K |
| Interest Expense | 16.89M | 18.22M | 25.3M | 34.28M | 26.58M |
| Other Income / Expenses | (22.94M) | (21.19M) | (27.33M) | (46.39M) | (11.97M) |
| Income Before Tax | (14.83M) | (14.98M) | (21.59M) | (7.51M) | 14.78M |
| Pre-Tax Margin | -5.0% | -4.8% | -6.1% | -1.9% | 3.3% |
| Income Tax Expense | 7K | 4.21M | 9.1M | 5.85M | 5.01M |
| Net Income | (14.83M) | (19.19M) | (30.69M) | (13.36M) | 9.77M |
| Net Margin | -5.0% | -6.1% | -8.7% | -3.4% | 2.2% |
| EPS (Basic) | (0.38) | (0.48) | (0.75) | (0.32) | 0.22 |
| EPS (Diluted) | (0.38) | (0.48) | (0.75) | (0.32) | 0.21 |
| Weighted Avg Shares | 38.98M | 40.03M | 40.74M | 41.68M | 45.34M |
| Weighted Avg Shares (Diluted) | 38.98M | 40.03M | 40.74M | 41.68M | 47.16M |
Artivion, Inc.
NYSE:AORT
Intrinsic Alpha fair value
Locked
Current Price
$18.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.